Latest Iron News

Genmin Limited has successfully completed the first tranche of its capital raising, issuing over 131 million shares to fund its flagship Baniaka iron ore project in Gabon, targeting production by late 2026.

Magnetite Mines has cleared a crucial regulatory hurdle as its Razorback Iron Ore Project’s Mining Lease Proposal passes the South Australian Government’s validity assessment, paving the way for detailed technical review and public consultation.

Atomic Eagle Limited has begun trading on the ASX following a transformative merger, backed by a strong $20 million cash position to advance uranium exploration in Zambia. The company’s renewed strategy targets resource expansion at its flagship Muntanga Uranium Project.

Atomic Eagle Ltd, formerly known as Tombador Iron Limited, will have its trading suspension lifted and be reinstated to quotation on the ASX starting 24 November 2025 after meeting key compliance requirements.

Iron Road Ltd's recent surface sampling at the Irria Prospect reveals promising concentrations of valuable heavy minerals, including titanium and zircon, paving the way for a targeted drilling campaign starting December 2025.

Champion Iron Limited has updated its dividend announcement, confirming an ordinary dividend of CAD 0.10 per share and its Australian Dollar equivalent for the first half of 2025.

Canadian Phosphate Limited has signed a non-binding Letter of Intent with Novaphos Inc. to explore advanced phosphate processing technology, aiming to produce high-grade phosphoric acid domestically for fertilizer and battery markets.

AIC Mines has reported encouraging drilling results from eight prospects at its Eloise Regional Project, highlighting high-grade gold and copper mineralisation and confirming new structural targets for further exploration.

Emeco Holdings projects steady earnings growth and robust cash flow for FY26, driven by sustained mining activity and disciplined capital spending.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.